in

BY THE NUMBERS

Compiled by Cari Kraft, Jacobs Management Group, Inc.

$854B

Pc0390600

The total 2015 revenue for the Top 50 Pharma companies reaches $854B, up from $834 in 2015.

Source: Healthcare Sales and Marketing Magazine “Top 50 Pharma Companies,” Healthcare Sales and Marketing Magazine, May 15, 2016.

8.25M

Pc0390400

8.2 million people have cumulatively enrolled in Obamacare. Enrollment is rising. Between Dec. 13, 2015 and Dec. 19, 2015, nearly 4.1 million people selected a plan, far ahead of 2014.

Source: “Health Insurance Marketplace Open Enrollment Snapshot—Week 7”, CMS, December 22, 2015

$1.64B

Pc0390300

Healthcare online and mobile advertising spend continues to rise.

The US Healthcare and Pharmaceutical Industry will spend $1.64 billion on paid online and mobile advertising in 2015, up from $1.43 billion in 2014. This spending will rise to $2.55 billion by 2019.

Source: The US Healthcare and Pharma Industry 2015: Digital Ad Spending Forecasts and Trends, emarketer.com, May 25, 2015.

35%

Pc0390500

Healthcare Data is at risk!

A surprising number of data breaches, 35% were in the healthcare industry. Source: Identity Theft Research Center, “Data Breach Reports,” December 31, 2015.

$1.2B

Pc0390100

The 3D printing market arrives!

The Global 3D printing market is estimated to grow quickly spurred by tissue engineering and dental implants.

Source: ”3D Printing in Healthcare Market – By Material (Donor Cells, Plastics, Metals, Ceramics, Bone Cement); By Application (Implants, Tissue Engineering, Surgical Guides, Hearing Aids, Dental Implants, Medical Components) — Forecast (2015 to 2020)”, IndustryArc, April 14, 2016.

60%

Pc0390200

The FDA is getting faster?

27 of the 45 novel drugs approved in 2015 by the FDA were designated in one or more expedited categories to help speed the development and/or approval process. These include Alecensa, Avycaz, Bridion, Cholbam, Corlanor, Cotellic, Cresemba, Daklinza, Darzalex, Empliciti, Entresto, Farydak, Genvoya, Ibrance, Kanuma, Lenvima, Lonsurf, Ninlaro, Orkambi, Portrazza, Praxbind, Strensiq, Tagrisso, Unituxin, Viberzi, Xuriden, and Yondelis.

Source: “2015 Novel Drugs Summary” January 2016, US Food and Drug Administration, Center for Drug Evaluation and Research.

82%

Pc0390700

Medical device company outlooks are positive.

82% of the survey participants in Emergo’s recent Medical Device Industry Outlook had a positive outlook for 2016. The strongest growth is expected by those in North America for the US, 42%, and those in Europe and Asia for China, 30% and 49% respectively.

Source: Medical Device and Insutry Outlook, Emergo, January 2016.

What do you think?

Written by hsandm

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Loading…

0

Climbing Toward Peak Sales

PHARMA PHRENZY: THE TOP 50